These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

828 related items for PubMed ID: 17912154

  • 1. Glucocorticoids and 11beta-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome.
    Stimson RH, Walker BR.
    Minerva Endocrinol; 2007 Sep; 32(3):141-59. PubMed ID: 17912154
    [Abstract] [Full Text] [Related]

  • 2. Is 11beta-hydroxysteroid dehydrogenase type 1 a therapeutic target? Effects of carbenoxolone in lean and obese Zucker rats.
    Livingstone DE, Walker BR.
    J Pharmacol Exp Ther; 2003 Apr; 305(1):167-72. PubMed ID: 12649365
    [Abstract] [Full Text] [Related]

  • 3. 11β-Hydroxysteroid dehydrogenase type 1: relevance of its modulation in the pathophysiology of obesity, the metabolic syndrome and type 2 diabetes mellitus.
    Pereira CD, Azevedo I, Monteiro R, Martins MJ.
    Diabetes Obes Metab; 2012 Oct; 14(10):869-81. PubMed ID: 22321826
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a promising therapeutic target.
    Wamil M, Seckl JR.
    Drug Discov Today; 2007 Jul; 12(13-14):504-20. PubMed ID: 17631244
    [Abstract] [Full Text] [Related]

  • 5. 11beta-hydroxysteroid dehydrogenase type 1 and obesity.
    Morton NM, Seckl JR.
    Front Horm Res; 2008 Jul; 36():146-164. PubMed ID: 18230901
    [Abstract] [Full Text] [Related]

  • 6. Obesity and corticosteroids: 11beta-hydroxysteroid type 1 as a cause and therapeutic target in metabolic disease.
    Morton NM.
    Mol Cell Endocrinol; 2010 Mar 25; 316(2):154-64. PubMed ID: 19804814
    [Abstract] [Full Text] [Related]

  • 7. Tissue production of cortisol by 11beta-hydroxysteroid dehydrogenase type 1 and metabolic disease.
    Walker BR, Andrew R.
    Ann N Y Acad Sci; 2006 Nov 25; 1083():165-84. PubMed ID: 17148739
    [Abstract] [Full Text] [Related]

  • 8. Is the metabolic syndrome an intracellular Cushing state? Effects of multiple humoral factors on the transcriptional activity of the hepatic glucocorticoid-activating enzyme (11beta-hydroxysteroid dehydrogenase type 1) gene.
    Iwasaki Y, Takayasu S, Nishiyama M, Tsugita M, Taguchi T, Asai M, Yoshida M, Kambayashi M, Hashimoto K.
    Mol Cell Endocrinol; 2008 Mar 26; 285(1-2):10-8. PubMed ID: 18313835
    [Abstract] [Full Text] [Related]

  • 9. Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 in antidiabetic therapy.
    Wang M.
    Handb Exp Pharmacol; 2011 Mar 26; (203):127-46. PubMed ID: 21484570
    [Abstract] [Full Text] [Related]

  • 10. 11-Dehydrocorticosterone causes metabolic syndrome, which is prevented when 11β-HSD1 is knocked out in livers of male mice.
    Harno E, Cottrell EC, Keevil BG, DeSchoolmeester J, Bohlooly-Y M, Andersén H, Turnbull AV, Leighton B, White A.
    Endocrinology; 2013 Oct 26; 154(10):3599-609. PubMed ID: 23832962
    [Abstract] [Full Text] [Related]

  • 11. Type 2 diabetes and metabolic syndrome are associated with increased expression of 11beta-hydroxysteroid dehydrogenase 1 in obese subjects.
    Alberti L, Girola A, Gilardini L, Conti A, Cattaldo S, Micheletto G, Invitti C.
    Int J Obes (Lond); 2007 Dec 26; 31(12):1826-31. PubMed ID: 17593901
    [Abstract] [Full Text] [Related]

  • 12. 11beta-hydroxysteroid dehydrogenase type 1 inhibitors for metabolic syndrome.
    Schnackenberg CG.
    Curr Opin Investig Drugs; 2008 Mar 26; 9(3):295-300. PubMed ID: 18311666
    [Abstract] [Full Text] [Related]

  • 13. 11Beta-hydroxysteroid dehydrogenase type 1 in human disease: a novel therapeutic target.
    Tomlinson JW.
    Minerva Endocrinol; 2005 Mar 26; 30(1):37-46. PubMed ID: 15877012
    [Abstract] [Full Text] [Related]

  • 14. Carbenoxolone treatment attenuates symptoms of metabolic syndrome and atherogenesis in obese, hyperlipidemic mice.
    Nuotio-Antar AM, Hachey DL, Hasty AH.
    Am J Physiol Endocrinol Metab; 2007 Dec 26; 293(6):E1517-28. PubMed ID: 17878220
    [Abstract] [Full Text] [Related]

  • 15. 11beta-hydroxysteroid dehydrogenase type 1 as a modulator of glucocorticoid action: from metabolism to memory.
    Seckl JR, Walker BR.
    Trends Endocrinol Metab; 2004 Nov 26; 15(9):418-24. PubMed ID: 15519888
    [Abstract] [Full Text] [Related]

  • 16. Cortisol--cause and cure for metabolic syndrome?
    Walker BR.
    Diabet Med; 2006 Dec 26; 23(12):1281-8. PubMed ID: 17116176
    [Abstract] [Full Text] [Related]

  • 17. Anti-diabetic and anti-adipogenic effects of a novel selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor in the diet-induced obese mice.
    Park JS, Rhee SD, Jung WH, Kang NS, Kim HY, Kang SK, Ahn JH, Kim KY.
    Eur J Pharmacol; 2012 Sep 15; 691(1-3):19-27. PubMed ID: 22760069
    [Abstract] [Full Text] [Related]

  • 18. Antidiabetic effects of 11beta-HSD1 inhibition in a mouse model of combined diabetes, dyslipidaemia and atherosclerosis.
    Lloyd DJ, Helmering J, Cordover D, Bowsman M, Chen M, Hale C, Fordstrom P, Zhou M, Wang M, Kaufman SA, Véniant MM.
    Diabetes Obes Metab; 2009 Jul 15; 11(7):688-99. PubMed ID: 19527482
    [Abstract] [Full Text] [Related]

  • 19. 11 beta-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome.
    Wake DJ, Walker BR.
    Mol Cell Endocrinol; 2004 Feb 27; 215(1-2):45-54. PubMed ID: 15026174
    [Abstract] [Full Text] [Related]

  • 20. Sub-chronic administration of the 11beta-HSD1 inhibitor, carbenoxolone, improves glucose tolerance and insulin sensitivity in mice with diet-induced obesity.
    Taylor A, Irwin N, McKillop AM, Flatt PR, Gault VA.
    Biol Chem; 2008 Apr 27; 389(4):441-5. PubMed ID: 18225986
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.